-
2024-519655-28-00
5
Premenopausal patients with high-risk HR-positive/HER2-negative breast
-
2025-520725-20-00
4
Surgical site infection
-
2024-516582-36-00
10
2026-05-01
Early stage HER2-positive breast cancer
-
2024-517131-52-00
5
2025-11-03
Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lym
-
2024-519827-16-00
5
2025-09-30
Newly Diagnosed Transplant Ineligible Multiple Myeloma Patients
-
2024-518154-16-00
5
2025-08-27
non-small cell lung cancer
-
2023-510294-34-00
5
2025-06-12
small lymphocytic lymphoma (SLL)
-
2023-506817-23-01
5
2025-05-23
Metastatic hormone naïve prostate cancer (mHNPC)
-
2024-515526-89-00
4
2025-05-16
Diffuse Large B-Cell Lymphoma (DLBCL)
-
2024-516009-22-00
5
2025-04-30
myelodysplastic neoplasms/syndromes (MDS)
-
2024-512279-10-00
5
2024-11-25
Triple Negative Breast Cancer
-
2022-500587-35-01
5
2023-07-06
Stroke
-
2023-510384-36-00
5
2022-09-13
Newly Diagnosed Multiple Myeloma
-
2023-504931-42-00
4
2021-04-06
Chronic lymphocytic leukemia/Small lymphocytic lymphoma; Richters tran
-
2024-513958-29-00
5
2025-04-24
Cardiovascular disorders: Hypertension and Obesity
-
2024-512998-27-00
5
2025-02-21
Non-Small Cell Lung Cancer
-
2024-511306-23-00
5
2024-07-01
Breast cancer, colon cancer, rectal cancer, stomach cancer, oesophagea
-
2023-510463-35-00
4
2023-04-26
Patients with KRASG12C-mutant NSCLC, including patients aged ≥18 years
-
2024-514173-22-00
5
2023-02-28
Cystic Fibrosis
-
2023-509429-37-00
5
2022-10-03
Advanced or Metastatic Non-Small Cell Lung Cancer
-
2024-512749-18-00
4
2022-03-03
Newly diagnosed Multiple Myeloma
-
2023-507961-24-00
5
2021-04-19
High-Risk HER2-Positive Breast Cancer
-
2023-507263-19-00
5
2020-12-23
Advanced Non-Small Cell Lung Cancer
-
2023-510390-33-00
5
2020-10-23
HER2-negative breast cancer patients with high relapse risk after
stan